Immunization of BALB/c mice with peptide HVSGHRMAWDMMMNWA, encompassing residues 121-135 from hepatitis C virus E1 protein, induced CD4 ⍣ T h 1 cells as well as a long-lasting CD8 ⍣ cytotoxic T lymphocyte (CTL) response in vivo when the peptide was administered s.c. with or without incomplete Freund's adjuvant. Using truncated peptides from this sequence it was shown that the determinant recognized by cytotoxic T cells was encompassed by residues SGHRMAWDM. Deletion of residues from the N-terminus or the C-terminus of the wild-type peptide abrogated its helper character. When Val122 of the wild peptide was replaced by Ala, the ability to induce a cytotoxic response was lost concomitantly with the loss of the T h 1 pattern of cytokine production. Interestingly, the Ala-modified peptide, when co-immunized with a peptide encompassing residues 323-329 from ovalbumin (OVA), which is able to induce a T h 1 response in BALB/c mice, restored the capacity of the modified peptide to induce CTL. However, co-immunization of the Ala-modified peptide with a peptide encompassing residues 106-118 from sperm whale myoglobin, which induces a T h 0 cytokine profile in BALB/c mice, was much less efficient than the OVA peptide to restore CTL induction. These results demonstrate that CTL induction with a short synthetic peptide requires that this peptide contains domains recognized by T c cells as well as by T h 1 cells. For those peptides that do not contain this type of T h domain, competent T cell help can be provided by co-immunization with a distinct peptide that is able to stimulate a T h 1 response.
Introduction

Induction of cytotoxic T lymphocytes (CTL) is an important
(TD c ) (23) (24) (25) (26) or mixtures of TD h and TD c peptides not covalently linked (27) (28) (29) . defensive mechanism of the immune system in response to infection with a virus or other pathogens (1) (2) (3) (4) (5) (6) . This induction Because synthetic peptides do not have any of the potential dangers associated with the induction of an infection, due to plays a key role in the elimination of infected cells. Similarly, it is also known that tumor growth can be controlled by CTL recombinant viruses, the use of peptides might be more acceptable for human therapy. Thus, understanding the (7-9). Because of the great potential of CTL in cancer therapy and in the treatment of viral infections, a number of groups molecular mechanisms of how synthetic peptides induce CTL is of paramount importance. Experiments carried out by others have attempted to develop immunization strategies to induce CTL. Thus, the successful use of recombinant viruses (10-12), as well as by our group (19, (23) (24) (25) demonstrated that CTL induction with synthetic peptides requires T cell help. Also, it dendritic cells (DC) pulsed with antigens (13,14), particulate antigens (15, 16) , lipopeptides (17) and synthetic peptides has been reported that during infection a T h 1 cytokine profile is required to induce CTL (30, 31) . All these considerations has been reported. In this last case, several alternative approaches have been tested: short synthetic peptides suggest that short synthetic peptides, that are able to induce a CTL response in vivo, should encompass a TD h (probably (18) (19) (20) (21) (22) , peptide constructs containing a determinant recognized by T h cells (TD h ) and a determinant recognized by CTL of the T h 1 subtype) and a TD c in their sequence.
To study the requirements of a short synthetic peptide to with or without 5 µg/ml of peptide and different numbers of effector cells in triplicate. Spontaneous release was measured induce CTL in vivo, we selected a peptide from hepatitis C virus (HCV) E1 protein encompassing residues 121-135 that from wells without effector cells and maximum release from target cells incubated with 5% Triton X-100. The spontaneous we had proved was able to induce a CTL response (32) . Further characterization in the present study showed that release was in all cases Ͻ25% of total release. In selected experiments, 0.1 mg/ml of different antibodies was added E1(121-135) induced CTL CD8 ϩ and T h 1 CD4 ϩ responses in vivo when immunized in incomplete Freund's adjuvant (IFA).
during the incubation period. After 4 h of incubation, supernatants were harvested and radioactivity measured in a Using truncated peptides, we studied the regions within the peptide responsible for T h and T c recognition. With the aim scintillation counter (Topcount; Packard, Meridan, CT). In CTL precursor frequency measurement experiments, of abolishing the ability of the peptide to induce a CD4 ϩ T h response and concomitantly its ability to induce a CTL four different concentrations of LN cells (8ϫ10 5 , 4ϫ10 5 , 2ϫ10 5 and 1ϫ10 5 ) were placed in 24 replica cultures (for each response, we replaced Val122 by Ala, affording E1(121-135, Ala122). As expected, replacement of this putative anchor dilution) in culture medium in the presence of 10 µg/ml of peptide E1(121-135), complemented with graded numbers residue of the T h moiety of peptide E1(121-135) abrogated the induction of T h response. This opened the possibility of of irradiated syngenic spleen cells (3000 rad) to give a total number of 5ϫ10 5 cells/well (96-wells U-bottomed plates) in a studying the effect of extrinsic T cell help on CTL induction by co-immunization of E1(121-135, Ala122) with two peptides final volume of 0.25 ml of medium. After 6 days of culture at 37°C and 5 % CO 2 , CTL activity of each individual well was that were able to induce T h 1 and T h 0 cytokine profiles respectively. These experiments shed more light not only in measured using the 51 Cr-release assay by transferring 100 µl of each well to a plate containing radiolabeled P815 cells the understanding of how synthetic peptides can induce CTL responses, but also on how these responses can be and peptide E1(121-135), and another 100 µl to a plate with P815 radiolabeled cells without peptide. After 5 h of culture, manipulated.
50 µl of supernatant were removed from each well and the percentage of lysis estimated in a scintillation counter Methods (Topcount). Responses for the individual wells were considered positive when CTL activity in the presence of peptide Peptide synthesis was 15% higher than in the absence of peptide. Frequencies Peptides were synthesized by the solid-phase method of were calculated using χ 2 analysis according to the method Merrifield (33) using the F-moc alternative (34) and a manual of Taswell (38) on a computer program (kindly provided to multiple solid-phase peptide synthesizer (35) . The ninhydrin us by Dr L. Selin, University of Massachusetts Medical Center, test of Kaiser was used to monitor every step (36) . At the end Worcester, MA). CTL precursor frequencies were calculated of the synthesis, peptides were cleaved and deprotected, on the regression curve by interpolating the number of and washed 6 times with diethyl ether. They were lyophilized responder cells required to give 37% negative cultures. Only and analyzed by HPLC. The purity of peptides was Ͼ80% as those experiments where data fitted in the single-hit model judged by HPLC.
were considered.
Mice
Immunization for cytokine measurement Six-week-old female BALB/c mice were purchased from IFFA Groups of three mice were immunized by s.c. injection at the Credo (Barcelona, Spain). They were hosted in appropriate base of the tail and footpads with 60 µg of peptide emulsified animal care facilities and handled following international in IFA. Ten days after the primary injection, animals were guidelines required for experimentation with animals.
killed and LN cells removed. The lymphocytes were then plated on 96-well plates at 8ϫ10 5 cells/well with culture Immunization and measurement of CTL response medium alone or with serial dilutions of peptide in the same medium to a final volume of 0.25 ml. In selected experiments, Groups of three mice were immunized by s.c. injection at the base of the tail and footpads with 60 µg of peptide emulsified 0.1 mg/ml of different antibodies was added during the incubation period. Supernatants (50 µl) were removed 24 h in IFA at days 0 and 15. For immunizations using a TD h and a TD c peptide mixture, 60 µg of each peptide was injected.
later to measure IL-2 content, and 48 h later for IFN-γ and IL-4. In some experiments, immunizations were carried out in the Measurement of cytokine production absence of adjuvant. This was done by i.p. injection of 60 µg of peptide in 0.5 ml of saline at days 0, 7 and 14. In both IL-2 content in culture supernatants was measured by using a CTLL bioassay as described (39). IFN-γ production was protocols the animals were killed 10 days after the last immunization and their lymph nodes (LN) and/or spleen measured by ELISA (Genzyme, Cambridge, MA) according to manufacturer's instructions. IL-4 content was measured by removed. Cells (8ϫ10 6 /well) were re-stimulated in vitro in 24-well plates in 2 ml of culture medium (RPMI 1640 supple-CT4S bioassay (kindly provided by Drs W. E. Paul and G. J.
Watson, National Institutes of Health, Bethesda, MD). Briefly, mented with 10% FCS, 2 mM glutamine, penicillin 100 U/ml, streptomycin 100 µg/ml and 5ϫ10 -5 M 2-mercaptoethanol) CT4S cells were re-supended in culture medium and were plated (5ϫ10 3 cells/well) in a 96-well flat-bottomed plate with with 5 µg/ml of peptide. Cytotoxic activity was measured 5 days after initial culture using the 51 Cr-release assay (37) . the supernatant to be assayed (50% v/v). After 48 h of culture, cells were pulsed with 0.5 µCi/well of [ 3 H]thymidine for 18 h, P815 target cells (10 6 cells) were radiolabeled with 50 µCi of Na 2 51 CrO 4 at 37°C for 1 h, washed 3 times, and incubated harvested and thymidine incorporation was determined in a scintillation counter (Topcount). Standard curves using known amounts of rIL-4 were also included to determine the amount of IL-4.
Depletion of CD4 ϩ and CD8 ϩ cells in vivo
Mice were depleted of CD4 ϩ or CD8 ϩ cells by i.p. injection of 0.3 mg of anti-CD4 (obtained from rat anti-mouse hybridoma GK1-5) or anti-CD8 (obtained from rat anti-mouse hybridoma H35.17.2) antibodies respectively on days -1, 0, 1, 6, 7, 8, 13, 14 and 15 as previously described (19,40); day 0 being the day of immunization. The efficiency of depletions was assessed by flow cytometry on day 21.
Results
Immunization with peptide E1(121-135) induced a CD8 ϩ CTL response
In a first experiment, BALB/c mice were immunized with peptide E1(121-135) from HCV E1 protein in IFA. As shown in Fig. 1 (Fig. 1C) . In order to identify the region of E1(121-135) recognized by CD8 ϩ cells, LN cells from BALB/c mice immunized with E1(121-135) were stimulated in vitro with E1(121-135) for 5 days and their CTL activity measured against P815 cells pulsed with a number of truncated peptides. Since truncated peptides SGHRMAWDMMMNWA and HVSGHRMAWDM were equally active, and share the region SGHRMAWDM, it was concluded that this region is the one recognized by induced CTL. This was confirmed when using nonapeptide SGHRMAWDM in the CTL assay (Fig. 2) .
Immunization with peptide E1(121-135) stimulated a CD4 ϩ T h 1 cytokine profile and concomitantly CTL induction
To characterize the cytokine profile induced after immunization with E1(121-135), LN cells from BALB/c mice immunized Table 1 , the pattern of cytokine production was of the T h 1 presence of 5 µg/ml of peptide. CTL activity was measured using P815 target cells previously incubated with 5 µg/ml of E1(121-135) subtype, i.e. high IL-2 and IFN-γ production, and no detectable or with medium alone. The phenotype of the CTL induced with IL-4. Experiments carried out in the presence or absence of peptide E1(121-135) was characterized using P815 target cells anti-CD4 or anti-CD8 antibodies showed that only CD4 ϩ cells incubated with E1(121-135) in the presence or in the absence of were responsible for cytokine production. To characterize the 0.1 mg/ml of anti-CD4 or anti-CD8 antibodies plus complement (C).
region of E1(121-135) responsible for T h cell activity, LN cells from BALB/c mice immunized with E1(121-135) were stimulated in vitro with 40 µg/ml of wild-type peptide or with a number of truncated peptides (Table 2) . Results show that of CTL by immunization with peptide E1(121-135) in the absence of adjuvant. Mice were immunized at days 0, 7 deletion of residues from either the N-terminus or the Cterminus substantially decreases IL-2 production, showing and 14 with 60 µg of E1(121-135) in 0.5 ml of saline. Animals were sacrificed at day 21 and their spleen cells that the entire sequence is required to provide T cell help.
In another group of experiments, we studied the induction stimulated for 5 days in the presence of E1(121-135). As shown in Fig. 3 , this strategy of immunization was also able E1(121-135) in 0.5 ml of saline. As shown in Fig. 3 , depletion of either CD4 ϩ cells or CD8 ϩ cells completely abrogated CTL induction, indicating that both types of cells are needed. (Table 3) . Moreover, no CTL were induced after immunization supernatants were harvested 24 h later and production of IL-2 was with E1(121-135, Ala122) ( Ala, the peptide was not recognized (Fig. 6) .
Peptide E1(121-135) induced a long-lasting response
We then carried out experiments to restore the CTL activity of this peptide by providing external T cell help and characterize the type of T cell help required. As shown in Table 3 , immunization with T h peptides OVA(323-339) (encompassing residues 323-339 from ovalbumin) and FIS (encompassing Table 3 . Patterns of cytokine production after immunization residues 106-118 from sperm whale myoglobin) elicited with different peptides T h 1 and T h 0 cytokine profiles respectively. Thus, we decided to use these peptides to provide external T cell help to In order to get a further insight on the magnitude of the CTL responses induced after these immunizations, the T cell precursor frequency was measured by limiting dilution assay. As shown in Table 4 , the T cell precursor frequency is in good agreement with the percentage of specific lysis induced (Fig. 5) . That is, co-immunization of E1(121-135, Ala122) with OVA(323-339) affords a frequency of CTL similar to the one attained with Mice were immunized with peptide E1(121-135), with E1(121-135, 122Ala), with E1(121-135, 122Ala) in conjunction with the T h 1 peptide OVA(323-339) or with E1(121-135, 122Ala) in conjunction with the T h 0 peptide FIS emulsified in IFA. LN cells were stimulated in vitro in the presence of E1 (121-135) or E1(121-135, 122Ala ) peptides and the CTL precursor frequency measured after 5 days as described in Methods. or immunogenic constructs containing combinations of CD4 of cytokines required for efficient CTL induction. Thus, we selected two TD h peptides, OVA(323-339) and FIS, that are and CD8 epitopes (23) (24) (25) (26) . In most of these cases, it was reported that a TD h should be present in the peptide. Also, able to induce a T h 1 and a T h 0 cytokine profile respectively. As shown in Fig. 5 and Table 4 , the external T cell help as known from in vivo models, when a pathogen enters the body, CTL induction is helped by activation of CD4 ϩ cells of provided by the T h 1 peptide was able to efficiently restore CTL induction, whereas the use of T h 0 peptide under our the T h 1 subtype. Thus, we hypothesized that short synthetic peptides that are able to induce a CTL response should experimental conditions restored CTL activity only partially. This result indicates that T h peptides that are able to induce contain two types of determinants: those recognized by CD4 ϩ T h 1 cells and those recognized by CD8 ϩ cells. To address this T h 1 cytokine profiles are more efficient (if not essential) to induce CTL in vivo than peptides that elicit T h 0 profiles. In hypothesis we selected peptide E1(121-135) from hepatitis C virus E1 protein which we had found was able to induce a vitro studies with CD4 ϩ and CD8 ϩ subpopulations stimulated with synthetic peptides have demonstrated the importance of CTL response in BALB/c mice. Characterization of the cytokine profile induced by this peptide showed a T h 1 cytokine profile different cytokines in CTL induction. Thus, IL-2 and IFN-γ are important in early stages of induction, whereas IL-4 is utilized mediated by CD4 ϩ cells. Also, depletion of CD4 ϩ or CD8 ϩ cells in mice before immunization with peptide E1 (121) (122) (123) (124) (125) (126) (127) (128) (129) (130) (131) (132) (133) (134) (135) in later stages of CTL maturation (44) . It has been reported that IL-12 secretion (one of the most powerful T h 1 skewing completely abrogated the ability of this peptide to induce CTL in vivo, demonstrating that both types of cells are required cytokines) by DC is dependent upon interaction with CD4 ϩ T h 1 cells, whereas CD4 ϩ T h 2 cells inhibit IL-12 secretion (45) . for CTL induction. Moreover, using truncated peptides from E1(121-135) we showed that the region recognized by CTL Thus 'good' levels of IL-2 and IFN-γ, and low production of IL-4 might be important for CTL induction. However, as we is encompassed by amino acids 123-131 and that the whole peptide E1(121-135) was necessary for providing efficient T and others have recently demonstrated (46) (47) (48) , very high levels of IL-12 and IFN-γ may have a suppressive effect on cell help for CTL induction.
To study the role of the TD h encompassed by E1(121-135) the induction of T h 1 and CTL responses. Thus, 'adequate' levels of these cytokines are essential for an efficient CTL we replaced Val122 by Ala to give peptide E1(121-135, Ala122). This was done because Val122 might be an anchor induction. It has been recently reported that CD4 ϩ T cell help for CTL residue for binding to MHC class II molecules, as described for other peptides having TD h character (42) . Replacement induction can be bypassed by activation of DC through CD40, suggesting that the critical role of T h cells for CTL induction of Val122 completely abrogated IL-2 and IFN-γ production (Table 3) as well as CTL induction, showing that Val122 is is activation through the CD40-CD40 ligand (49) (50) (51) . Thus, immunogenic synthetic peptides should contain TD h and TD c essential for providing efficient T cell help. Since only the region encompassed by amino acids 123-131 is the one in order to activate CD4 ϩ T h cells and CD8 ϩ CTL as well as DC through their cognate interaction with CD4 ϩ cells. Some recognized by CTL, replacement of Val122 did not alter the CD8 epitope in peptide E1(121-135, Ala122). Thus, changes 9-10mer synthetic peptides (that because of their short length might not have TD h character) are nevertheless able to induce in CTL induction can only be attributed to abrogation of the CD4 ϩ T h response. Moreover, target cells pulsed with peptide a CTL response when immunized pulsed onto DC (14,52). In these cases, DC might be either activated in vitro under E1(121-135, Ala122) were efficiently recognized by E1(121-135)-specific CTL, showing that the modified peptide had a culture conditions or the peptides might themselves be able to activate DC by an alternative pathway independent of competent CD8 epitope, and retained the ability to be processed and presented by antigen-presenting cell class I CD40-CD40 ligand, as some viruses do (50). Because in our model depletion of CD4 ϩ cells in vivo abrogated CTL induction molecules (Fig. 6 ). Since E1(121-135, Ala122) was not immunogenic per se but contained a TD c , it opened the we believe that this induction was achieved via a CD4 ϩ -dependent pathway. possibility of studying the effect of an external TD h peptide to induce CTL in vivo, in a similar manner to the study carried It is interesting to note that the CTL response induced by peptide E1(121-135) was long-lasting and could also be out by Shirai et al. (43) where they tested the use of intrinsic and extrinsic helper epitopes for CTL induction. However, induced in the absence of adjuvant. These results suggest that the use of combinations of TD c and T h 1 TD h regions in these authors did not study the cytokine profiles induced by the helper peptides. In our work we wished to study the type immunogenic constructs might be a useful tool in human with peptide E1(121-135) in IFA (data not shown). We are
